Top

Published in:

Open Access 01-03-2011 | Symposium-In-Writing

2011: the immune hallmarks of cancer

Authors: Federica Cavallo, Carla De Giovanni, Patrizia Nanni, Guido Forni, Pier-Luigi Lollini

Published in: Cancer Immunology, Immunotherapy | Issue 3/2011

Abstract

Ten years after the publication of the position paper “The hallmarks of cancer” (Hanahan and Weinberg Cell 100:57–70, 2000), it has become increasingly clear that mutated cells on their way to giving rise to a tumor have also to learn how to thrive in a chronically inflamed microenvironment, evade immune recognition, and suppress immune reactivity. Genetic and molecular definition of these three immune hallmarks of cancer offers the opportunity to learn how to deploy specific countermeasures to reverse the situation in favor of the immune system and, eventually, the patient. This new information could be channeled to address what seem to be the three major hallmarks for the immune control of cancer progression: effective procedures to activate immune reactivity; characterization of not-disposable oncoantigens; and counteraction of immune suppression.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70CrossRefPubMed

Lazebnik Y (2010) What are the hallmarks of cancer? Nat Rev Cancer 10:232–233CrossRefPubMed

Maeda S, Kamata H, Luo JL, Leffert H, Karin M (2005) IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121:977–990. doi:10.1016/j.cell.2005.04.014 CrossRefPubMed

Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–759. doi:10.1038/nri1703 CrossRefPubMed

Grohmann U, Bronte V (2010) Control of immune response by amino acid metabolism. Immunol Rev 236:243–264. doi:1600-065X.2010.00915.x CrossRefPubMed

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. doi:10.1038/nature07205 CrossRefPubMed

Caruso C, Lio D, Cavallone L, Franceschi C (2004) Aging, longevity, inflammation, and cancer. Ann NY Acad Sci 1028:1–13CrossRefPubMed

Vasto S, Carruba G, Lio D, Colonna-Romano G, Di BD, Candore G, Caruso C (2009) Inflammation, ageing and cancer. Mech Ageing Dev 130:40–45. doi:10.1016/j.mad.2008.06.003 CrossRefPubMed

Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5:828–831. doi:10.1038/10552 CrossRefPubMed

10.

Mantovani A (2009) Cancer: Inflaming metastasis. Nature 457:36–37. doi:10.1038/457036b CrossRefPubMed

11.

Calogero RA, Cordero F, Forni G, Cavallo F (2007) Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. Breast Cancer Res 9:211. doi:10.1186/bcr1745 CrossRefPubMed

12.

Warren MA, Shoemaker SF, Shealy DJ, Bshar W, Ip MM (2009) Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice. Mol Cancer Ther 8:2655–2663. doi:10.1158/1535-7163.MCT-09-0358 CrossRefPubMed

13.

Sangaletti S, Tripodo C, Ratti C, Piconese S, Porcasi R, Salcedo R, Trinchieri G, Colombo MP, Chiodoni C (2010) Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Cancer Res 70:7764–7775. doi:10.1158/0008-5472.CAN-10-0471 CrossRefPubMed

14.

Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461–466. doi:10.1038/nature02924 CrossRefPubMed

15.

Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296. doi:10.1016/j.cell.2004.07.013 CrossRefPubMed

16.

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081. doi:10.1093/carcin/bgp127 CrossRefPubMed

17.

El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398–402. doi:10.1038/35006081 CrossRefPubMed

18.

Thomas L (1959) Discussion. In: Lawrence HS (ed) Cellular and humoral aspects of the hypersensitivity states. Hoeber-Herper, New York, pp 529–532

19.

Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1–27PubMed

20.

Stutman O (1974) Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183:534–536CrossRefPubMed

21.

Rygaard J, Povlsen CO (1976) The nude mouse vs. the hypothesis of immunological surveillance. Transplant Rev 28:43–61PubMed

22.

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107–1111. doi:10.1038/35074122 CrossRefPubMed

23.

Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903–907. doi:10.1038/nature06309 CrossRefPubMed

24.

Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360. doi:10.1146/annurev.immunol.22.012703.104803 CrossRefPubMed

25.

Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59–67. doi:10.1016/S0140-6736(07)61050-2 CrossRefPubMed

26.

Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B, Kiessling R (2006) Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res 66:6387–6394. doi:10.1158/0008-5472.CAN-06-0029 CrossRefPubMed

27.

Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Seliger B, Kiessling R (2009) HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother 58:653–664. doi:10.1007/s00262-008-0587-1 CrossRefPubMed

28.

Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117–158CrossRefPubMed

29.

Seliger B (2008) Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 57:1719–1726. doi:10.1007/s00262-008-0515-4 CrossRefPubMed

30.

Nicoletti G, De Giovanni C, Lollini PL, Bagnara GP, Scotlandi K, Landuzzi L, Del Re B, Zauli G, Prodi G, Nanni P (1989) In vivo and in vitro production of haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding. Eur J Cancer Clin Oncol 25:1281–1286CrossRefPubMed

31.

Melani C, Chiodoni C, Forni G, Colombo MP (2003) Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102:2138–2145. doi:10.1182/blood-2003-01-0190 CrossRefPubMed

32.

McLean K, Buckanovich RJ (2008) Myeloid cells functioning in tumor vascularization as a novel therapeutic target. Transl Res 151:59–67. doi:10.1016/j.trsl.2007.11.002 CrossRefPubMed

33.

Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, Zou W (2004) Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 64:5535–5538. doi:10.1158/0008-5472.CAN-04-1272 CrossRefPubMed

34.

Colombo MP, Piconese S (2007) Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 7:880–887. doi:10.1038/nrc2250 CrossRefPubMed

35.

Rochman Y, Spolski R, Leonard WJ (2009) New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9:480–490. doi:10.1038/nri2580 CrossRefPubMed

36.

Wing K, Sakaguchi S (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11:7–13. doi:10.1038/ni.1818 CrossRefPubMed

37.

Ernst PB, Garrison JC, Thompson LF (2010) Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol 185:1993–1998. doi:10.4049/jimmunol.1000108 CrossRefPubMed

38.

Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501–507. doi:10.1016/S1470-2045(09)70035-X CrossRefPubMed

39.

Mantovani A, Romero P, Palucka AK, Marincola FM (2008) Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371:771–783. doi:10.1016/S0140-6736(08)60241-X CrossRefPubMed

40.

Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, Forster I, Huss R, Weber WA, Kneilling M, Rocken M (2008) TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13:507–518. doi:10.1016/j.ccr.2008.04.001 CrossRefPubMed

41.

Beatty PL, Narayanan S, Gariepy J, Ranganathan S, Finn OJ (2010) Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila) 3:438–446. doi:10.1158/1940-6207.CAPR-09-0194 CrossRef

42.

Katsumata M, Okudaira T, Samanta A, Clark DP, Drebin JA, Jolicoeur P, Greene MI (1995) Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med 1:644–648CrossRefPubMed

43.

Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di CE, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini PL (2001) Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 194:1195–1205CrossRefPubMed

44.

Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101:1348–1355. doi:10.1093/jnci/djp288 CrossRefPubMed

45.

zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350. doi:10.1038/nrc798 CrossRefPubMed

46.

Schiller JT, Castellsague X, Villa LL, Hildesheim A (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26(Suppl 10):K53–K61. doi:10.1016/j.vaccine.2008.06.002 CrossRefPubMed

47.

Welters MJ, Kenter GG, van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, Ramwadhdoebe TH, Piersma SJ, van der Hulst JM, Valentijn AR, Fathers LM, Drijfhout JW, Franken KL, Oostendorp J, Fleuren GJ, Melief CJ, van der Burg SH (2010) Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 107:11895–11899. doi:10.1073/pnas.1006500107 CrossRefPubMed

48.

Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, Moreels A, Haumont M, Bollen A, Smets F, Denis M (2007) Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 196:1749–1753. doi:10.1086/523813 CrossRefPubMed

49.

Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA, Owen K, Royed C, Stevens SJ, Shroff RC, Tanday MK, Wilson AD, Middeldorp JM, Amlot PL, Steven NM (2009) A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 88:1025–1029. doi:10.1097/TP.0b013e3181b9d918 CrossRefPubMed

50.

Lollini PL, Cavallo F, Nanni P, Forni G (2006) Vaccines for tumour prevention. Nat Rev Cancer 6:204–216. doi:10.1038/nrc1815 CrossRefPubMed

51.

Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3:630–641. doi:10.1038/nri1150 CrossRefPubMed

52.

Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F, Ria F (2006) Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 177:7626–7633PubMed

53.

Rolla S, Ria F, Occhipinti S, Di SG, Iezzi M, Spadaro M, Nicolo C, Ambrosino E, Merighi IF, Musiani P, Forni G, Cavallo F (2010) Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. J Immunol 184:6124–6132. doi:10.4049/jimmunol.0901215 CrossRefPubMed

54.

Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, Astolfi A, Iezzi M, Di CE, Musiani P, Forni G, Lollini PL (2004) Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol 173:2288–2296PubMed

55.

Quaglino E, Rolla S, Iezzi M, Spadaro M, Musiani P, De Giovanni C, Lollini PL, Lanzardo S, Forni G, Sanges R, Crispi S, De LP, Calogero R, Cavallo F (2004) Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 113:709–717. doi:10.1172/JCI19850 PubMed

56.

Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC, Berzofsky JA (2005) Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 174:4228–4236PubMed

57.

Nanni P, Pupa SM, Nicoletti G, De Giovanni C, Landuzzi L, Rossi I, Astolfi A, Ricci C, De VR, Invernizzi AM, Di CE, Musiani P, Forni G, Menard S, Lollini PL (2000) p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 87:186–194CrossRefPubMed

58.

Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68:3077–3080. doi:10.1158/0008-5472.CAN-07-3293 CrossRefPubMed

59.

Kmieciak M, Knutson KL, Dumur CI, Manjili MH (2007) HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 37:675–685. doi:10.1002/eji.200636639 CrossRefPubMed

60.

Jones KL, Buzdar AU (2009) Evolving novel anti-HER2 strategies. Lancet Oncol 10:1179–1187. doi:10.1016/S1470-2045(09)70315-8 CrossRefPubMed

61.

Cavallo F, Calogero RA, Forni G (2007) Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer 7:707–713. doi:10.1038/nrc2208 CrossRefPubMed

62.

Chiarle R, Martinengo C, Mastini C, Ambrogio C, D’Escamard V, Forni G, Inghirami G (2008) The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 14:676–680. doi:10.1038/nm1769 CrossRefPubMed

63.

Lollini PL, Nicoletti G, Landuzzi L, Cavallo F, Forni G, De Giovanni C, Nanni P (2011) Vaccines and other immunological approaches for cancer immunoprevention. Curr Drug Targets (in press)

64.

Berta GN, Sprio AE, Iezzi M, Spadaro M, Cappia S, Salamone P, Di Scipio F, Mognetti B, Papotti M, Musiani P, Forni G, Cavallo F (2011) A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters. Cancer Prev Res (in press)

65.

Shevach EM (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389–400. doi:10.1038/nri821 PubMed

66.

Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263–274. doi:10.1038/nrc1586 CrossRefPubMed

67.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949. doi:10.1038/nm1093 CrossRefPubMed

68.

Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, Kroemer G, Martin F, Chauffert B, Zitvogel L (2005) Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+ CD25+ regulatory T cell proliferation. J Exp Med 202:919–929. doi:10.1084/jem.20050463 CrossRefPubMed

69.

Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307. doi:10.1038/nri1806 CrossRefPubMed

70.

Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591–1602. doi:10.1084/jem.20042167 CrossRefPubMed

71.

Piconese S, Valzasina B, Colombo MP (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205:825–839. doi:10.1084/jem.20071341 CrossRefPubMed

72.

Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174. doi:10.1038/nri2506 CrossRefPubMed

73.

Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59:1593–1600. doi:10.1007/s00262-010-0855-8 CrossRefPubMed

74.

DeNardo DG, Andreu P, Coussens LM (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 29:309–316. doi:10.1007/s10555-010-9223-6 CrossRefPubMed

75.

Cipriani B, Fridman A, Bendtsen C, Dharmapuri S, Mennuni C, Pak I, Mesiti G, Forni G, Monaci P, Bagchi A, Ciliberto G, La Monica N, Scarselli E (2008) Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum Gene Ther 19:670–680. doi:10.1089/hum.2007.127 CrossRefPubMed

76.

Ugel S, Delpozzo F, Desantis G, Papalini F, Simonato F, Sonda N, Zilio S, Bronte V (2009) Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 9:470–481. doi:10.1016/j.coph.2009.06.014 CrossRefPubMed

77.

Schuster S, Neelapu S, Gause B, Muggia F, Gockerman J, Sotomayor E, Winter J, Flowers C, Stergiou A, Kwak L, for the BiovaxID Phase III study investigators (2009) Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. J Clin Oncol 27: 2

78.

Schwartzentruber D, Lawson D, Richards J, Conry R, Miller D, Gailani F, Riley L, Vena D, Hwu P (2009) A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210 M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 27:CRA9011

79.

Couzin-Frankel J (2010) Immune therapy steps up the attack. Science 330:440–443. doi:10.1126/science.330.6003.440 CrossRefPubMed

80.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422. doi:10.1056/NEJMoa1001294 CrossRefPubMed

81.

Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767–774. doi:10.1038/nrd3229 CrossRefPubMed

82.

Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317–327. doi:10.1038/nri2744 CrossRefPubMed

83.

Wikinvest (2010) www.wikinvest.com/stock

84.

Ferris RL, Jaffee EM, Ferrone S (2010) Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28:4390–4399. doi:10.1200/JCO.2009.27.6360 CrossRefPubMed

85.

Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S, Fu YX (2010) The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18:160–170. doi:10.1016/j.ccr.2010.06.014 CrossRefPubMed

Title: 2011: the immune hallmarks of cancer
Authors: Federica Cavallo
Carla De Giovanni
Patrizia Nanni
Guido Forni
Pier-Luigi Lollini
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 3/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-010-0968-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges

Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer

Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro

A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination

Lymphadenectomy exacerbates tumor growth while lymphadenectomy plus the adoptive transfer of autologous cytotoxic cells and low-dose cyclophosphamide induces regression of an established murine fibrosarcoma

In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models

Keynote webinar | Spotlight on antibody–drug conjugates in cancer